国际内分泌代谢杂志
國際內分泌代謝雜誌
국제내분비대사잡지
International Journal of Endocrinology and Metabolism
2015年
6期
388-391
,共4页
1型糖尿病%胰淀素%肠促胰素治疗%胰岛素样生长因子%免疫治疗
1型糖尿病%胰澱素%腸促胰素治療%胰島素樣生長因子%免疫治療
1형당뇨병%이정소%장촉이소치료%이도소양생장인자%면역치료
Type 1 diabetes mellitus%Amylin%Incretin-based therapies%Insulin-like growth factors%Immunotherapeutic agents
1型糖尿病的病理特征为胰岛素的绝对缺乏,胰岛素治疗是目前1型糖尿病治疗的基石.胰淀素、肠促胰素、自身免疫反应等因素参与了1型糖尿病的发展.1型糖尿病患者胰岛素治疗联合胰岛素增敏剂、α-糖苷酶抑制剂、胰淀素、肠促胰素及免疫抑制剂可能在降低血糖、减少胰岛素用量方面获益,但益处和风险仍需进一步研究证实.
1型糖尿病的病理特徵為胰島素的絕對缺乏,胰島素治療是目前1型糖尿病治療的基石.胰澱素、腸促胰素、自身免疫反應等因素參與瞭1型糖尿病的髮展.1型糖尿病患者胰島素治療聯閤胰島素增敏劑、α-糖苷酶抑製劑、胰澱素、腸促胰素及免疫抑製劑可能在降低血糖、減少胰島素用量方麵穫益,但益處和風險仍需進一步研究證實.
1형당뇨병적병리특정위이도소적절대결핍,이도소치료시목전1형당뇨병치료적기석.이정소、장촉이소、자신면역반응등인소삼여료1형당뇨병적발전.1형당뇨병환자이도소치료연합이도소증민제、α-당감매억제제、이정소、장촉이소급면역억제제가능재강저혈당、감소이도소용량방면획익,단익처화풍험잉수진일보연구증실.
The pathogenic mechanism of type 1 diabetes mellitus (T1 DM) is absolute deficit of insulin, and insulin remains the cornerstone of T1DM management.Amylin, incretin and autoimmune response may play roles in the development of T1DM.Insulin sensitizing agents, α-glucosidase inhibitors,amylin, incretin-based therapies and immunotherapeutic agents adjuvant to insulin in patients with T1DM may reduce blood glucose and the dose of insulin, whereas, the benefits and risks are still under evaluation.
